These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 7494409)

  • 1. Treatment of cystic fibrosis based on understanding CFTR.
    Smith AE
    J Inherit Metab Dis; 1995; 18(4):508-16. PubMed ID: 7494409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cystic fibrosis transmembrane conductance regulator-mRNA delivery: a novel alternative for cystic fibrosis gene therapy.
    Bangel-Ruland N; Tomczak K; Fernández Fernández E; Leier G; Leciejewski B; Rudolph C; Rosenecker J; Weber WM
    J Gene Med; 2013; 15(11-12):414-26. PubMed ID: 24123772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular heterogeneity of CFTR expression and function in the lung: implications for gene therapy of cystic fibrosis.
    Jiang Q; Engelhardt JF
    Eur J Hum Genet; 1998 Jan; 6(1):12-31. PubMed ID: 9781011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenovirus 5-fiber 35 chimeric vector mediates efficient apical correction of the cystic fibrosis transmembrane conductance regulator defect in cystic fibrosis primary airway epithelia.
    Granio O; Ashbourne Excoffon KJ; Henning P; Melin P; Norez C; Gonzalez G; Karp PH; Magnusson MK; Habib N; Lindholm L; Becq F; Boulanger P; Zabner J; Hong SS
    Hum Gene Ther; 2010 Mar; 21(3):251-69. PubMed ID: 19788389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel natural product compound enhances cAMP-regulated chloride conductance of cells expressing CFTR[delta]F508.
    deCarvalho AC; Ndi CP; Tsopmo A; Tane P; Ayafor J; Connolly JD; Teem JL
    Mol Med; 2002 Feb; 8(2):75-87. PubMed ID: 12080183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repairing the basic defect in cystic fibrosis - one approach is not enough.
    Farinha CM; Matos P
    FEBS J; 2016 Jan; 283(2):246-64. PubMed ID: 26416076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding how cystic fibrosis mutations cause a loss of Cl- channel function.
    Sheppard DN; Ostedgaard LS
    Mol Med Today; 1996 Jul; 2(7):290-7. PubMed ID: 8796909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystic fibrosis and the use of pharmacogenomics to determine surrogate endpoints for drug discovery.
    Eidelman O; Zhang J; Srivastava M; Pollard HB
    Am J Pharmacogenomics; 2001; 1(3):223-38. PubMed ID: 12083969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fixing cystic fibrosis by correcting CFTR domain assembly.
    Okiyoneda T; Lukacs GL
    J Cell Biol; 2012 Oct; 199(2):199-204. PubMed ID: 23071149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of delta F508 cystic fibrosis transmembrane conductance regulator protein and related chloride transport properties in the gallbladder epithelium from cystic fibrosis patients.
    Dray-Charier N; Paul A; Scoazec JY; Veissière D; Mergey M; Capeau J; Soubrane O; Housset C
    Hepatology; 1999 Jun; 29(6):1624-34. PubMed ID: 10347100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting CFTR: how to treat cystic fibrosis by CFTR-repairing therapies.
    Amaral MD
    Curr Drug Targets; 2011 May; 12(5):683-93. PubMed ID: 21039334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Therapies to Correct the Cystic Fibrosis Basic Defect.
    Bergeron C; Cantin AM
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34201249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional characterization of a novel CFTR mutation P67S identified in a patient with atypical cystic fibrosis.
    Kraus C; Reis A; Naehrlich L; Dötsch J; Korbmacher C; Rauh R
    Cell Physiol Biochem; 2007; 19(5-6):239-48. PubMed ID: 17495464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy for cystic fibrosis: cystic fibrosis transmembrane conductance regulator mutation-specific pharmacologic strategies.
    Rubenstein RC
    Mol Diagn Ther; 2006; 10(5):293-301. PubMed ID: 17022692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding how cystic fibrosis mutations disrupt CFTR function: from single molecules to animal models.
    Wang Y; Wrennall JA; Cai Z; Li H; Sheppard DN
    Int J Biochem Cell Biol; 2014 Jul; 52():47-57. PubMed ID: 24727426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CFTR-NHERF2-LPA₂ Complex in the Airway and Gut Epithelia.
    Zhang W; Zhang Z; Zhang Y; Naren AP
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28869532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [From the laboratory to the clinic: CFTR and the therapeutic options for cystic fibrosis].
    Mayol J; Alvarez de Arcaya Vicente A; Arbeo Escolar AM; Peña Soria MJ; Alvarez Fernández-Represa J
    An Med Interna; 2000 Feb; 17(2):92-8. PubMed ID: 10829466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.
    Bell SC; De Boeck K; Amaral MD
    Pharmacol Ther; 2015 Jan; 145():19-34. PubMed ID: 24932877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin C controls the cystic fibrosis transmembrane conductance regulator chloride channel.
    Fischer H; Schwarzer C; Illek B
    Proc Natl Acad Sci U S A; 2004 Mar; 101(10):3691-6. PubMed ID: 14993613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spliceosome-mediated RNA trans-splicing with recombinant adeno-associated virus partially restores cystic fibrosis transmembrane conductance regulator function to polarized human cystic fibrosis airway epithelial cells.
    Liu X; Luo M; Zhang LN; Yan Z; Zak R; Ding W; Mansfield SG; Mitchell LG; Engelhardt JF
    Hum Gene Ther; 2005 Sep; 16(9):1116-23. PubMed ID: 16149910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.